Vivanta Industries Limited reported a consolidated net profit of ₹97.82 lakh for the quarter ended June 30, 2026 (Q1FY26), compared to a net profit of ₹53.94 lakh in the corresponding quarter of FY25. The company’s revenue from operations stood at ₹8,022.22 lakh for the quarter, an increase from ₹7,588.50 lakh in Q1FY25. This marks a return to profitability from a loss of ₹80.37 lakh reported in the preceding quarter (Q4FY25). The Board of Directors approved the unaudited standalone and consolidated financial results during its meeting held on July 29, 2026, at the company’s registered office in Ahmedabad.

The meeting, originally scheduled for July 24, 2026, was postponed due to adverse weather conditions. In addition to approving the financial results, the Board took note of several governance matters, including the declaration of independence by independent directors under Section 149(7) of the Companies Act, 2013, and Regulation 25(8) of the SEBI Listing Regulations. The Board also noted the issuance of duplicate share certificates to Mr. Rajesh Bhanji Lakum under Regulation 39(3) of the SEBI Listing Regulations.

Key Financial Highlights

The company’s financial performance showed significant improvement in the first quarter of FY26. Consolidated total income reached ₹8,076.27 lakh, driven primarily by revenue from operations. Total expenses were recorded at ₹7,978.45 lakh. The profit before tax was ₹97.82 lakh, with no tax expense incurred for the quarter.

On a standalone basis, the company reported a net profit of ₹76.80 lakh for Q1FY26, compared to ₹32.89 lakh in Q1FY25. Standalone revenue from operations was ₹336.49 lakh, down significantly from ₹1,056.05 lakh in the same quarter last year, indicating that the majority of the group’s revenue is generated through its subsidiaries and joint ventures.

Strategic Developments

During the meeting, the Board took note of the execution of business collaboration agreements with Qness Pharmaceuticals, a proprietorship concern engaged in the manufacture, supply, branding, and marketing of pharmaceutical and allied products. This collaboration aligns with the company’s diversified activities in pharmaceuticals and healthcare. The Board also authorized designated signatories to open trading and demat accounts with Motilal Oswal Financial Services Limited (MOFSL).

What the Numbers Show

The sharp contrast between the standalone and consolidated results highlights Vivanta Industries’ reliance on its group entities for revenue generation. While standalone revenue declined by approximately 68% year-on-year, consolidated revenue grew by nearly 6%, suggesting robust performance in its subsidiary operations. The turnaround from a quarterly loss of ₹80.37 lakh in Q4FY25 to a profit of ₹97.82 lakh in Q1FY26 underscores improved operational efficiency or favorable mix shifts within the group. Investors should monitor whether this profitability trend sustains as the company expands its pharmaceutical partnerships.

Vivanta Industries has submitted its audited financial results for the quarter and year ended March 31, 2026, confirming compliance with regulatory disclosure requirements. The statutory auditors, M/S. GMCA & CO, Chartered Accountants, Ahmedabad, have issued an audit report with an unmodified opinion on the company's financial performance for the period.

The declaration was made in compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates the submission of audited results to the stock exchanges to ensure transparency and adherence to disclosure norms.

The audit report covers the financial statements for the full fiscal year ending March 31, 2026. An unmodified opinion indicates that the auditors found the financial statements to be free of material misstatements and prepared in accordance with the applicable accounting standards.

Key Details of the Filing

The filing was submitted to BSE Limited on July 1, 2026, by H. A. Parikh, Managing Director of Vivanta Industries. The submission ensures that the audited financial results are available on the public record for shareholders and regulatory bodies.